Our proven methods were effective in assisting investors with the market last week. Below are some important performance statistics from the last three months.
Verona Pharma plc (NASDAQ:VRNA) will hold its Q4 2024 Earnings Conference Call on February 27, 2024, at 9:00 AM ET. The call will feature company leaders, including President and CEO David Zaccardelli, CFO Mark Hahn, and CCO Christopher Martin. Various analysts from firms like Jefferies, Piper Sandler, and Wells Fargo will also participate in the discussion.
Ohtuvayre TM (ensifentrine) achieved net product sales of $36.6 million in the fourth quarter and $42.3 million in 2024.
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) has announced that its senior management will give a presentation about the company at several conferences in March 2025.
Verona Pharma plc (Nasdaq: VRNA) has announced that it will share its financial results for the fourth quarter and the entire year ending December 31, 2024, on Thursday, February 27, 2025. The company will also hold a conference call for the investment community at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these results and give a corporate update.
If you're searching for stocks that are likely to continue their recent growth, Verona Pharma (VRNA) might be a good option. It is among the stocks that have successfully gone through our "Recent Price Strength" filter.
Verona Pharma (VRNA) might be a good option for investors interested in short-term gains from stocks that are fundamentally strong. It is among the stocks that have successfully met our criteria for short-term trading strategies.
Verona Pharma (VRNA) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
If you're searching for stocks that are likely to keep rising, Verona Pharma (VRNA) might be a good option. It is among the stocks that have successfully gone through our "Recent Price Strength" filter.
Verona Pharma's new COPD treatment, Ohtuvayre, made $36 million in sales in the fourth quarter, showing a strong demand for new therapies. Even with its high price, Ohtuvayre's wide approval and strong interest from doctors suggest it could earn more than anticipated in annual sales. The company has $336 million in cash, which should support its operations until at least the end of 2026.